ID
42518
Description
Study ID: 106464 Clinical Study ID: 106464 Study Title: A Study of the Efficacy Against Episodes of Clinical Malaria Due to P. Falciparum Infection of GSK Biologicals Candidate Vaccine RTS, S/AS01, Administered According to a 0,1,2-months Schedule in Children Aged 5 to 17 Months Living in Tanzania & Kenya Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00380393 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GSK malaria vaccine 257049 Vaccine, Sanofi-Pasteur's Human Diploid Cell Rabies Vaccine Trade Name: N/A Study Indication: Malaria ODM derived from https://clinicaltrials.gov/ct2/show/study/NCT00380393. This Phase IIb randomized, double-blind, controlled study of the efficacy against episodes of clinical malaria due to Plasmodium falciparum infection of GlaxoSmithKline Biologicals’ candidate vaccine RTS, S/AS01E, administered IM according to a 0, 1, 2-month vaccination schedule in children aged 5 months to 17 months living in Tanzania and Kenya. This study includes the following 7 clinical study visits (3 different visit types) during a double-blind phase (Day -60 to Month 6 1/2) and a single-blind phase including an extension for a subset of patients (month 7 to month 14). Clinical visit 1: Baseline visit, screening, and randomisation (DAY -60 to 0) Clinical visit 2: Vaccination I (MONTH 0, DAY 0 | DOSE 1 | 0 - 60 DAYS AFTER VISIT 1) Clinical visit 3: Vaccination II (MONTH 1, DAY 30 | DOSE 2 | 21 - 35 DAYS AFTER VISIT 2) Clinical visit 4: Vaccination III (MONTH 2, DAY 60 | DOSE 3 | 21 - 35 DAYS AFTER VISIT 3) Clinical visit 5: Blood Sample, ACD (MONTH 3, DAY 90 | 21 - 42 DAYS AFTER VISIT 4) Clinical visit 6: Blood Sample, ACD (MONTH 6 1/2 | CROSS-SECTIONAL VISIT FOR ACD | FINAL STUDY VISIT FOR DOUBLE-BLIND PHASE) Clinical visit 7: Blood Sample, ACD (MONTH 14 | FINAL STUDY VISIT SINGLE-BLIND PHASE) Field-worker home visits: During the vaccination period, clinical visits are accompanied by daily field-worker visits for a one-week period subsequent to each vaccine administration at clinical visits 2, 3, and 4 (visit code 21-26 following clinical visit 2; visit code 27-32 following clinical visit 3; visit code 33-38 following clinical visit 4). After completion of the vaccination period, clinical visits are then accompanied by weekly field-worker home visits (visit code 39-40 following clinical visit 4/dose 3; visit code 41-55 following clinical visit 5; visit code 56-86 following clinical visit 6). These visits serve the additional purpose of Active Case Detection (ACD). Passive Case Detection (PCD) for clinical malaria disease is performed both during the course of the double-blind (day -60 to month 6 1/2) and the single-blind phase (month 7 to month 14). Solicited and unsolicited adverse events form should be documented following vaccinations at visit 2 (dose 1), visit 3 (dose 2) and visit 4 (dose 3) whenever the subject experiences any of the listed signs/symptoms during the solicited period or any serious or non-serious unsolicited adverse events within 30 days post-vaccination. If any of these adverse events meets the protocol definition of serious, please complete a Serious Adverse Event report and fax to GSK Biologicals Study Contact for SAE reporting within 24 hours. Note that informed consent has to be obtained prior to any study procedure.
Link
https://clinicaltrials.gov/ct2/show/study/NCT00380393
Keywords
Versions (1)
- 8/11/21 8/11/21 -
Copyright Holder
GlaxoSmithKline
Uploaded on
August 11, 2021
DOI
To request one please log in.
License
Creative Commons BY-NC 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Efficacy of P. Falciparum Vaccine Against Malaria in Children NCT00380393
Solicited and Unsolicited Adverse Events
- StudyEvent: ODM
Description
Solicited Adverse Events Local Symptoms
Alias
- UMLS CUI-1
- C0877248
- UMLS CUI-2
- C1517001
- UMLS CUI-3
- C1457887
- UMLS CUI-4
- C0205276
- UMLS CUI-5
- C0150312
Description
If [Y] Yes, please tick No/Yes for each symptom. If Yes is ticked, please complete all respective items in the following two item groups. If any of these adverse events meets the protocol definition of serious, please complete a Serious Adverse Event report and fax to GSK Biologicals Study Contact for SAE reporting within 24 hours.
Data type
text
Alias
- UMLS CUI [1,1]
- C0037088
- UMLS CUI [1,2]
- C2700396
- UMLS CUI [1,3]
- C0042196
- UMLS CUI [1,4]
- C0687676
Description
If yes is ticked, please complete all respective items in the following two item groups.
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0038999
- UMLS CUI [1,2]
- C2700396
- UMLS CUI [1,3]
- C0150312
Description
If yes is ticked, please complete all respective items in the following two item groups.
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0030193
- UMLS CUI [1,2]
- C2700396
- UMLS CUI [1,3]
- C0150312
Description
Solicited Adverse Events Local Symptoms
Alias
- UMLS CUI-1
- C0877248
- UMLS CUI-2
- C1517001
- UMLS CUI-3
- C1457887
- UMLS CUI-4
- C0205276
- UMLS CUI-5
- C2348235
Description
If symptom has been ticked in previous item group, please complete all respective items in this item group for day 0 to day 6 post vaccination.
Data type
integer
Alias
- UMLS CUI [1,1]
- C0439228
- UMLS CUI [1,2]
- C0687676
- UMLS CUI [1,3]
- C0042196
Description
Only to be completed if swelling has been selected in previous item group.
Data type
integer
Measurement units
- mm
Alias
- UMLS CUI [1,1]
- C0038999
- UMLS CUI [1,2]
- C0456389
- UMLS CUI [1,3]
- C2700396
Description
Please indicate the intensity for solicited symptoms (pain). Only to be completed if pain has been selected in previous item group.
Data type
integer
Alias
- UMLS CUI [1,1]
- C0518690
- UMLS CUI [1,2]
- C0030193
- UMLS CUI [1,3]
- C2700396
Description
Solicited Adverse Events Local Symptoms
Alias
- UMLS CUI-1
- C0877248
- UMLS CUI-2
- C1517001
- UMLS CUI-3
- C1457887
- UMLS CUI-4
- C0205276
- UMLS CUI-5
- C0449238
Description
If symptom details have been quantified in the previous item group, please select the respective symptom and complete all items in this item group.
Data type
text
Alias
- UMLS CUI [1,1]
- C1457887
- UMLS CUI [1,2]
- C0205276
Description
If yes, please indicate the date of the last day of symptoms in the following item.
Data type
boolean
Alias
- UMLS CUI [1,1]
- C1457887
- UMLS CUI [1,2]
- C2700396
- UMLS CUI [1,3]
- C0549178
Description
Date in time last symptoms
Data type
date
Alias
- UMLS CUI [1,1]
- C0011008
- UMLS CUI [1,2]
- C1517741
- UMLS CUI [1,3]
- C1457887
Description
Solicited Adverse Events General Symptoms
Alias
- UMLS CUI-1
- C0877248
- UMLS CUI-2
- C1517001
- UMLS CUI-3
- C0159028
- UMLS CUI-4
- C0150312
Description
If [Y] Yes, please tick No/Yes for each symptom. If Yes is ticked, please complete all respective items in the following two item groups. If any of these adverse events meets the protocol definition of serious, please complete a Serious Adverse Event report and fax to GSK Biologicals Study Contact for SAE reporting within 24 hours.
Data type
text
Alias
- UMLS CUI [1,1]
- C0037088
- UMLS CUI [1,2]
- C0687676
- UMLS CUI [1,3]
- C0042196
Description
Fever is defined as axillary temperature > 37.5°C, oral temperature > 37.5°C, or rectal temperature > 38.0°C. If yes is ticked, please complete all respective items in the following two item groups.
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0015967
- UMLS CUI [1,2]
- C0150312
Description
Please consider axillary measurement [A] to be the preferable route.
Data type
text
Alias
- UMLS CUI [1,1]
- C0005903
- UMLS CUI [1,2]
- C0449687
Description
If yes is ticked, please complete all respective items in the following two item groups.
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0022107
- UMLS CUI [1,2]
- C0150312
Description
If yes is ticked, please complete all respective items in the following two item groups.
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0013144
- UMLS CUI [1,2]
- C0150312
Description
If yes is ticked, please complete all respective items in the following two item groups.
Data type
boolean
Alias
- UMLS CUI [1,1]
- C1971624
- UMLS CUI [1,2]
- C0150312
Description
Solicited Adverse Events General Symptoms
Alias
- UMLS CUI-1
- C0877248
- UMLS CUI-2
- C1517001
- UMLS CUI-3
- C0159028
- UMLS CUI-4
- C2348235
Description
If symptom has been ticked in previous item group, please complete all respective items in this item group for day 0 to day 6 post vaccination.
Data type
integer
Alias
- UMLS CUI [1,1]
- C0439228
- UMLS CUI [1,2]
- C0687676
- UMLS CUI [1,3]
- C0042196
Description
Only to be completed if Fever [FE] has been selected in previous item group.
Data type
float
Measurement units
- °C
Alias
- UMLS CUI [1,1]
- C0005903
- UMLS CUI [1,2]
- C0449687
Description
Only to be completed if [FE] has been selected in previous item group.
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0005903
- UMLS CUI [1,2]
- C1272696
Description
Only to be completed if Irritability/Fussiness [IR] has been selected in previous item group. Please indicate the intensity for solicited symptoms (irritability / fussiness).
Data type
integer
Alias
- UMLS CUI [1,1]
- C0518690
- UMLS CUI [1,2]
- C0022107
Description
Only to be completed if drowsiness [DR] has been selected in previous item group. Please indicate the intensity for solicited symptoms (drowsiness).
Data type
integer
Alias
- UMLS CUI [1,1]
- C0518690
- UMLS CUI [1,2]
- C0013144
Description
Only to be completed if loss of appetite [LO] has been selected in previous item group. Please indicate the intensity for solicited symptoms (loss of appetite).
Data type
integer
Alias
- UMLS CUI [1,1]
- C0518690
- UMLS CUI [1,2]
- C1971624
Description
Solicited Adverse Events General Symptoms
Alias
- UMLS CUI-1
- C0877248
- UMLS CUI-2
- C1517001
- UMLS CUI-3
- C0159028
- UMLS CUI-4
- C0449238
Description
If symptom details have been quantified in the previous item group, please select the respective symptom and complete all items in this item group.
Data type
text
Alias
- UMLS CUI [1]
- C0159028
Description
If yes, please indicate the date of the last day of symptoms in the following item.
Data type
boolean
Alias
- UMLS CUI [1,1]
- C1457887
- UMLS CUI [1,2]
- C0549178
Description
Date in time last symptoms
Data type
date
Alias
- UMLS CUI [1,1]
- C0011008
- UMLS CUI [1,2]
- C1517741
- UMLS CUI [1,3]
- C1457887
Description
Please indicate the suspected causality between the vaccination and the selected symptom. Note that for Fever [FE], any Grade 3 temperature not related to vaccination should be entered as Causality “NO”. Alternative reasoning should be given in the following item.
Data type
text
Alias
- UMLS CUI [1,1]
- C0015127
- UMLS CUI [1,2]
- C0015967
- UMLS CUI [2,1]
- C0015127
- UMLS CUI [2,2]
- C0022107
- UMLS CUI [3,1]
- C0015127
- UMLS CUI [3,2]
- C0013144
- UMLS CUI [4,1]
- C0015127
- UMLS CUI [4,2]
- C1971624
Description
Note: This item should only be completed if fever (>39°C) non-related to vaccination (Causality “NO” in previous item) has occured.
Data type
text
Alias
- UMLS CUI [1,1]
- C0015127
- UMLS CUI [1,2]
- C0015967
Description
Unsolicited Adverse Events
Alias
- UMLS CUI-1
- C0877248
- UMLS CUI-2
- C4055646
Description
If [Y] Yes, fill in the Non-Serious Adverse Event section or Serious Adverse Event report, as appropriate.
Data type
text
Alias
- UMLS CUI [1,1]
- C1519255
- UMLS CUI [1,2]
- C4055646
- UMLS CUI [1,3]
- C0687676
- UMLS CUI [1,4]
- C0042196
- UMLS CUI [2,1]
- C1518404
- UMLS CUI [2,2]
- C4055646
- UMLS CUI [2,3]
- C0687676
- UMLS CUI [2,4]
- C0042196
Similar models
Solicited and Unsolicited Adverse Events
- StudyEvent: ODM
C0042210 (UMLS CUI [1,2])
C0042196 (UMLS CUI [2,1])
C0011008 (UMLS CUI [2,2])
C1517001 (UMLS CUI-2)
C1457887 (UMLS CUI-3)
C0205276 (UMLS CUI-4)
C0150312 (UMLS CUI-5)
C2700396 (UMLS CUI [1,2])
C0042196 (UMLS CUI [1,3])
C0687676 (UMLS CUI [1,4])
C2700396 (UMLS CUI [1,2])
C0150312 (UMLS CUI [1,3])
C2700396 (UMLS CUI [1,2])
C0150312 (UMLS CUI [1,3])
C1517001 (UMLS CUI-2)
C1457887 (UMLS CUI-3)
C0205276 (UMLS CUI-4)
C2348235 (UMLS CUI-5)
C0687676 (UMLS CUI [1,2])
C0042196 (UMLS CUI [1,3])
C0456389 (UMLS CUI [1,2])
C2700396 (UMLS CUI [1,3])
C0030193 (UMLS CUI [1,2])
C2700396 (UMLS CUI [1,3])
C1517001 (UMLS CUI-2)
C1457887 (UMLS CUI-3)
C0205276 (UMLS CUI-4)
C0449238 (UMLS CUI-5)
C2700396 (UMLS CUI [1,2])
C0549178 (UMLS CUI [1,3])
C1517741 (UMLS CUI [1,2])
C1457887 (UMLS CUI [1,3])
C1517001 (UMLS CUI-2)
C0159028 (UMLS CUI-3)
C0150312 (UMLS CUI-4)
C0687676 (UMLS CUI [1,2])
C0042196 (UMLS CUI [1,3])
C0150312 (UMLS CUI [1,2])
C0449687 (UMLS CUI [1,2])
C0150312 (UMLS CUI [1,2])
C0150312 (UMLS CUI [1,2])
C0150312 (UMLS CUI [1,2])
C1517001 (UMLS CUI-2)
C0159028 (UMLS CUI-3)
C2348235 (UMLS CUI-4)
C0687676 (UMLS CUI [1,2])
C0042196 (UMLS CUI [1,3])
C0449687 (UMLS CUI [1,2])
C1272696 (UMLS CUI [1,2])
C0022107 (UMLS CUI [1,2])
C0013144 (UMLS CUI [1,2])
C1971624 (UMLS CUI [1,2])
C1517001 (UMLS CUI-2)
C0159028 (UMLS CUI-3)
C0449238 (UMLS CUI-4)
C0549178 (UMLS CUI [1,2])
C1517741 (UMLS CUI [1,2])
C1457887 (UMLS CUI [1,3])
C0015967 (UMLS CUI [1,2])
C0015127 (UMLS CUI [2,1])
C0022107 (UMLS CUI [2,2])
C0015127 (UMLS CUI [3,1])
C0013144 (UMLS CUI [3,2])
C0015127 (UMLS CUI [4,1])
C1971624 (UMLS CUI [4,2])
C0015967 (UMLS CUI [1,2])
C4055646 (UMLS CUI-2)
C4055646 (UMLS CUI [1,2])
C0687676 (UMLS CUI [1,3])
C0042196 (UMLS CUI [1,4])
C1518404 (UMLS CUI [2,1])
C4055646 (UMLS CUI [2,2])
C0687676 (UMLS CUI [2,3])
C0042196 (UMLS CUI [2,4])